Cuba encouraged by early trials of homegrown COVID-19 vaccine


A nurse shows a dose of the Soberana-02 COVID-19 vaccine to be used in a volunteer as part of Phase III trials of the experimental Cuban vaccine candidate, amid concerns about the spread of the coronavirus disease (COVID-19), in Havana, Cuba, March 31, 2021. Jorge Luis Banos/Pool via REUTERS

HAVANA, June 19 (Reuters) – Cuba’s Soberana 2 vaccine candidate has shown 62% efficacy with just two of its three doses, state-run biopharmaceutical corporation BioCubaFarma said on Saturday, citing preliminary data from late phase trials.

Cuba, which has a decades-old reputed biotech sector, has five vaccine candidates in clinical trials, of which two – Soberana 2 and Abdala – are in late phase trials.

Reporting by Anett Rios
Writing by Sarah Marsh; Editing by David Gregorio

Our Standards: The Thomson Reuters Trust Principles.



Source link